Protecting Intellectual Property in Engagements with CMOs
Important IP contractual provisions should be included when working with CMOs.
Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.
Download
BioPharm International’s 2015 Outsourcing Resources eBook.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
